Introduction
Through the evolutionary process, retroviruses have targeted genes whose products are essential for a cell's normal physiological role within an organism. The targeted genes, referred to as proto-oncogenes, encode proteins that are key regulators for cell growth, dierentiation, survival or motility. Mutations in proto-oncogenes disrupt the regulated activity of the normal or wild-type gene product and the activity of the mutated protein confers a selective advantage for infected cells to survive over their non-infected counterparts. As we identify and characterize more proto-oncogenes and the proteins they encode, we are gaining a better understanding of the mechanisms that the wild-type proteins utilize to govern normal cellular physiology and the mechanisms that the oncogenic proteins utilize to ensure their evolutionary success. However, it is important to remember that oncoproteins do not function alone in the cell. In other words, the cellular signaling pathways that are activated or inactivated by an onco-protein are equally as important, as the onco-protein itself, for the oncogenic process to occur.
Historically, the morphological transformation of the mouse ®broblast cell line NIH3T3 has been used as a screen for oncogenes. DNA derived from human lung and colon tumors was transfected into NIH3T3 cells which led to the identi®cation of ras as a human oncogene (Cooper, 1982; Weinberg, 1981) . Further characterization of the ras oncogene determined that point mutations resulted in the activation of Ras, even though the signal transduction pathway that involved Ras had not been determined at the time (Reddy et al., 1982; Tabin et al., 1982; Yuasa et al., 1983) . It was over a decade later that Ras was identi®ed as an activator of Raf (Vojtek et al., 1993) . These earlier studies demonstrated that oncogenes are the mutated forms of cellular proteins. Even today, a common experimental approach to identify oncogenic genes is to isolate DNA from tumor cells and compare the nucleotide sequence relative to that of the protooncogene. This approach has led to the identi®cation of receptor tyrosine kinases (RTKs) as proto-oncogenes.
In order for an oncogene to be tumorigenic, there are many events that must occur within the cell. A change in the proto-oncogene nucleotide sequence occurs and the resulting gene product is a protein whose activity is not regulated like its wild-type counterpart. Cell proliferation has commonly been associated with the unregulated activity of oncogenes since cellular transformation is the phenotype that is observed in tumors. However, as we have learned more about signal transduction pathways and oncogenes, it is fair to state that cellular proliferation may be necessary, but it is not sucient, for a transformed cellular phenotype. Due to the pleiotropic nature of RTKs and the signaling proteins they activate, we are ®nding that maintenance of cell survival and motogenic pathways also play an important role in oncogenic signaling.
In the past, Ras has received much attention due to the high frequency of mutations that occur in the ras gene that is isolated from a variety of tumors. Because of this observation, scientists focused on Ras-dependent pathways and found that many RTKs produce a mitogenic signal through Ras. However, it has become apparent that tumors have properties that make them unique and that these properties are mediated by Ras-independent pathways. As an example, RTKs activate PI3-K whose lipid products function as second messengers to activate Akt which phosphorylates BAD, producing an anti-apoptotic signal for the cell. As a consequence, RTK activation of Ras-dependent and PI3-K-dependent pathways may contribute equally to produce a proliferative and an anti-apoptotic response, respectively. As a result of activating these two divergent pathways, mutated cells are allowed to selectively proliferate and those cells are not removed by normal apoptotic mechanisms. Therefore, multiple signaling pathways may be necessary for cellular transformation and no one pathway, alone, may be sucient to produce an oncogenic response. In the future, our knowledge of how these pathways are integrated may increase our chances of developing successful therapeutic strategies to treat malignant cancers, and possibly, allow us to develop strategies to prevent them from occurring. This review will focus on the mechanisms and pathways that cause RTKs and their substrate proteins to function as oncogenic proteins.
Receptor tyrosine kinases
Clearly, receptor tyrosine kinases can function as oncogenes. Over the past few years, numerous excellent reviews have appeared on RTKs and thè classical' SH2 (Src Homology 2) domain containing pathways they activate (Cohen et al., 1995; Ullrich and Schlessinger, 1990; van der Geer et al., 1994) . More recently, RTKs have been shown to utilize`novel' mechanisms to generate signals (reviewed in Weiss et al., 1997) . As we learn more about RTK-dependent signaling pathways, only time will allow us to dierentiate between classical and novel signaling pathways for RTKs. For purposes of this review, we will focus on RTKs and the signaling pathways they utilize that allows them to function as oncogenes. Since there are many oncogenic RTKs, we will discuss a select few in this review to highlight oncogenic mechanisms that involve RTKs.
RTKs are composed of an extracellular ligand binding domain, a transmembrane domain, an intracellular tyrosine kinase domain, and additional amino acid sequences that function as regulatory domains. Ligand binding induces receptor dimerization and autophosphorylation in a trans fashion, that is, one subunit of the dimer phosphorylates the opposing subunit. Phosphorylated tyrosines function to recruit intracellular signaling proteins, many via their SH2 domains. In addition, SH2-containing proteins, such as Grb2, function as adaptor proteins to recruit multiple proteins to RTKs, thus increasing the repertoire of signaling proteins that are activated by RTKs.
The Ras/Raf/MAPK pathway has received much attention over the last few years because it plays a major role in cellular proliferation. The link between RTKs and Ras that Grb2 provides clearly demonstrates the importance of this pathway in RTK signaling. However, we are learning more about the network of signaling molecules that are activated by RTKs. As a consequence, the physiological events that these pathways regulate also contribute to the oncogenic process. Accordingly, we need to characterize these pathways to gain a better understanding of the mechanisms that oncogenic RTKs utilize (Figure 1 ).
RET
Ret is a proto-type RTK oncogene because numerous, dierent mutations and gene rearrangements of the ret proto-oncogene have been isolated from tumor cells. For this reason, we will discuss Ret to illustrate the types of mutations that can occur in RTKs. The c-ret proto-oncogene encodes an RTK that also contains an extracellular cadherin-like domain and an interrupted tyrosine kinase domain, in addition to the aforementioned features of RTKs. The unglycosylated receptor is 120 kDa while neuroblastoma cells express a 150 and 170 kDa form of the receptor (Takahashi et al., 1991 . Ret expression occurs predominantly in neural crest-derived cells. The biological function of Ret is not well de®ned although expression studies suggest that Ret is involved in cell migration, proliferation, and dierentiation (Pachnis et al., 1993; Tsuzuki et al., 1995) . Ret knock-out mice die early during neonatal development and show severe renal abnormalities, demonstrating the importance of the Ret protein for embryonic development (Schuchardt et al., 1994) .
Missense, nonsense, and gene rearrangement of the ret proto-oncogene are the types of mutations that we will discuss. When missense mutations occur, an amino acid substitution is introduced into the resulting gene product which causes the protein to function in an unregulated manner, typically producing constitutive activity. In contrast, nonsense mutations introduce a stop codon within the coding sequence of the gene causing incomplete translation of the protein, resulting in a loss-of-function mutation. A gene rearrangement occurs when pieces of DNA, typically from dierent chromosomes, fuse to produce hybrid genes and the resulting protein activity is not regulated in a manner that is similar to that of the wild-type proteins. Although frameshift mutations occur in the ret protooncogene, they will not be discussed in this review.
Mutations in the c-ret proto-oncogene result in two classes of genetic diseases (reviewed in Edery et al., 1997; Mak and Ponder, 1996) . The developmental disorder, Hirschsprung's disease, is attributed to lossof-function mutations, while activating point mutations are associated with autosomally dominant inherited cancer syndromes of three types, multiple endocrine neoplasia (MEN) type 2A, MEN type 2B, and familial medullary thyroid carcinoma (FMTC). The extracellular domain of Ret is a hot spot for mutations. Individuals with the MEN 2A and FMTC syndromes have mutations in a cluster of ®ve cysteine codons in the extracellular domain of ret, (C609?R/W/Y), (Donis-Keller et al., 1993; Mulligan et al., 1993) . The net result of each of these missense mutations is ligand-independent activation of Ret tyrosine kinase activity. Additional missense mutations occur at codons 768 and 804 which are localized to the kinase domain and the kinase insert domain of the receptor. These mutations have been identi®ed from a few FMTC families demonstrating an oncogenic consequence of these mutations (Bolino et al., 1995; Eng et al., 1995) . However, the signaling pathways that are activated by these mutant receptors have not been characterized. The MEN 2B syndrome, although less common than MEN 2A, is associated with a M?T mutation at codon 918 of the second part of the tyrosine kinase domain (Carlson et al., 1994; Hofstra et al., 1994) . Similarly, the signaling pathway that mediates the oncogenic response for this receptor is not known, although constitutive activation of a signaling pathway probably mediates the oncogenic activity of this receptor.
In addition to speci®c point mutations, the ret proto-oncogene undergoes gene rearrangement. This phenomena was observed when DNA from human T cell lymphoma was transfected into NIH3T3 cells. DNA from the 3' end of the ret gene fused to the 5' end of unrelated DNA sequence, hence the name RET REarranged during Transfection, (Takahashi et al., 1985) . Although these DNA rearrangements were due to the experimental method, this ®nding suggested that the ret gene has a tendency to undergo DNA rearrangement. In fact, rearrangement of the 3' sequence of the ret proto-oncogene with the 5' sequences of H4/D10S170 Grieco et al., 1990) , the type Ia regulatory subunit of cyclic AMP-dependent protein kinase (Bongarzone et al., 1993) , and the ELE1 gene (Santoro et al., 1994a) have been detected from DNA extracts from papillary thyroid carcinomas (PTC). The resulting hybrid genes (Ret/ptc1, Ret/ptc2, and Ret/ptc3) consist of the Ret tyrosine kinase domain fused with genes that are capable of intracellular dimerization, thus producing Figure 1 Multiple pathways contribute to cellular transformation. Oncogenic receptor tyrosine kinases are pleiotropic, activating numerous intracellular signaling pathways. Grb2 and Shc (not shown) associate with activated receptors and participate in the activation of Ras, a small molecular weight GTP binding protein that functions upstream of sequential protein kinases of the MAPK pathway. Activation of MAPK is necessary for cellular proliferation, dierentiation, and cell scattering. In addition to activation of MAPK, oncogenic Ras stimulates the release of growth factors such as IGF-1. Acting in an autocrine fashion, IGF-1 stimulates its tyrosine kinase receptor which recruits and activates PI3-K, via the insulin receptor substrate 1 (IRS-1), to produce the phospholipids PI(3,4,5)P 3 and PI(3,4)P 2 . When bound to the PH domain of Akt, these phospholipids activate Akt to phosphorylate BAD and GSK3. When phosphorylated, BAD is an anti-apoptotic signal in cells. Akt phosphorylation of GSK3 results in inactivation of GSK3. This prevents the association of GSK3, APC and free b-catenin which would normally result in degradation of b-catenin. Instead, b-catenin can go on to aect gene transcription leading to proliferation and/or activation of anti-apoptotic pathways and APC can go on to play a role in cell motility. Oncogenic RTKs can also phosphorylate b-catenin, involved in cell-cell adhesion and the cytoskeleton, resulting in loss of the interaction of b-catenin with the actin cytoskeleton which could contribute to cell scattering. Thus, oncogenic RTKs are capable of using multiple, divergent mechanisms to undermine the normal physiological functions of cells hybrid proteins with a constitutively active Ret kinase. The Ret/ptc1 gene product, unlike the wild-type receptor, is localized to the cytoplasm and constitutively phosphorylated on tyrosine (Ishizaka et al., 1992) .
Only recently has the Ret ligand been identi®ed as glial cell-derived neurotrophic factor (GDNF (Durbec et al., 1996; Trupp et al., 1996) ). Prior to this discovery, a chimera of the extracellular ligand binding domain of the EGF-R and the intracellular domain of Ret was used to study Ret signaling pathways. Stimulation of cells expressing the EGF-R/ Ret chimera resulted in phosphorylation of paxillin, a cytoskeletal protein, and cellular transformation (Romano et al., 1994; Santoro et al., 1994b) . In addition, stimulation of the EGF-R/Ret chimera in SK-N-MC neuroepithelioma cells leads to cell scattering, growth inhibition, and loss of anchorageindependent growth (van Puijenbroek et al., 1997) . Characterization of the mitogen-activated protein kinase (MAPK) pathway from these cells indicated that ERK2 (extracellular signal-regulated kinase 2) was activated in a sustained fashion, suggesting that cell scattering correlates with sustained ERK2 activation. In contrast, a mitogenic response from EGF in PC12 cells correlates with transient ERK activation (Heasley and Johnson, 1992) .
Studies with the Ret/ptc2 oncogene have identi®ed phospholipase Cg (PLCg), Grb10 and Shc as signaling proteins with SH2 domains that associate with phosphorylated tyrosines of Ret/ptc2. Phosphotyrosine (pTyr)539, which is Tyr761 on the Ret protooncogene, and pTyr429 are the docking sites for PLCg and Grb10, respectively (Borrello et al., 1996) , while pTyr586 associates with Shc (Arighi et al., 1997) . Although the biological role of Ret is not well de®ned, the interaction of PLCg and Grb10 is not required for mitogenic signaling of Ret/ptc2.
Enigma is unique in that it associates with Ret/ptc2 via unphosphorylated Tyr586 demonstrating that unphosphorylated RTKs are capable of recruiting signaling proteins (Durick et al., 1996) . Additional data to support this observation came from experiments where kinase-inactive Ret/ptc2 was found to interact with Enigma in the yeast two-hybrid system, demonstrating that the kinase activity of Ret/ptc2 is not necessary for this interaction. However, the kinase activity of Ret/ptc2, as well as an interaction between Ret/ptc2 and Enigma, is necessary for Ret/ptc2 mitogenic signaling. The signaling pathways that are regulated by Ret are beginning to emerge. Now that many of the mutations in the ret proto-oncogene have been identi®ed, a careful analysis of the signaling pathways that are activated by the mutant proteins may shed light on new oncogenic pathways or reemphasize the importance of oncogenic pathways that have already been de®ned.
Hepatocyte growth factor receptor
Invasive cell growth is a component of the oncogenic process that contributes to the malignancy of tumor cells. Stimulation of the hepatocyte growth factor receptor (HGF-R) is particularly relevant to oncogenesis because this receptor stimulates invasive growth of carcinoma cells (Weidner et al., 1990) , is a potent angiogenic agent (Bussolino et al., 1992) , and is tumorigenic (Rong et al., 1992) . HGF, the ligand for the HGF-R, is also known as scatter factor because it stimulates cellular motility and functions as a morphoregulatory agent. HGF is a heterodimer composed of a 69 and a 34 kDa subunit which binds to the 190 kDa HGF/scatter factor (SF) receptor. HGF-R is a pleiotropic, epithelial cell receptor, capable of stimulating mitogenesis, motility, invasive growth and inducing branching tubulogenesis.
Following stimulation with HGF, many proteins associate with the receptor, become phosphorylated and/or become activated by the HGF-R. These proteins include PI3-K (Royal and , PLCg (Zhu et al., 1994) , Grb2 (Zhu et al., 1994) , Ras (Graziani et al., 1993) , focal adhesion kinase (Matsumoto et al., 1994) , b-catenin, plakoglobin (Shibamoto et al., 1994) and Shc (Pelicci et al., 1995) . Many of these proteins are activated by mitogenic growth factor receptors, such as the PDGF-R (Valius and Kazlauskas, 1993) . Like many RTKs, tyrosine phosphorylation within the kinase domain is required for catalytic activity (Longati et al., 1994) .
Little is known about the signaling pathways involving cell dissociation, motility, and morphogenesis that are mediated by the HGF-R. The HGF-R recruits a number of eector proteins including Grb2, Shc, the p85 regulatory subunit of PI3-K, PLCg and the phosphatase SHP2 by association with pTyr1356 (Zhu et al., 1994) . Grb2, Shc and PI3-K associate with pTyr489 (equivalent to Tyr1356 of Met or HGF-R) of the Tpr-Met oncoprotein (Fixman et al., 1995 (Fixman et al., , 1996 . Functionally, Tyr1356 is also necessary for transformation of ®broblasts mediated by Tpr-Met. Given our current understanding of the speci®city of SH2 domains, it seems counter intuitive to have so many proteins bind to the same phosphotyrosine.
More recently, Nguyen et al. (1997) have shown that phosphorylation of Tyr1356 is necessary for recruitment and phosphorylation of Gab1. However, association of Gab1 with the HGF-R is not direct, but mediated primarily by Grb2, where Grb2 functions as an adaptor between the two proteins. Thus, Gab1 may function as a docking site for the p85 subunit of PI3-K, PLCg, and SHP2 through Tyr1356. Of these signaling proteins, PI3-K activity is essential for HGF-Rmediated cell dissociation and subsequent scattering (Royal and Park, 1995) .
There is con¯icting data regarding the role of Tyr1356 in HGF-R signaling. Madin-Darby canine kidney (MDCK) cells expressing the Y1356F mutant HGF-R retain their ability to scatter but fail to stimulate tubulogenesis of tubular epithelial cells . In contrast, MDCK cells expressing a receptor chimera composed of the CSF-1R (extracellular domain)/Met (transmembrane and intracellular domain) and treated with CSF-1 fail to scatter, undergo invasive cell growth, and form branching tubules (Pasdar et al., 1997) . In addition, stimulation of the CSF-Met receptor inhibits cell-cell contact and junction formation, possibly by regulating E-cadherin and plakoglobin (reviewed in Daniel and Reynolds, 1997 ). E-cadherin may play a role in invasive cell growth mediated by the HGF-R since it is frequently down-regulated in metastatic tumors.
Receptor over-expression
One of the hallmarks of tumor cells is the overexpression of growth factor receptors. The epidermal growth factor receptor (EGF-R) is not mutated nor does it undergo gene rearrangement. However, overexpression of the EGF-R in many tumors, as well as association with the erbB-2 (Her-2/neu) oncogene and the c-cbl proto-oncogene, likely contributes to the oncogenic potential of the EGF-R as a stimulator of cell proliferation. In tumors, the EGF-R is frequently over-expressed which produces an autocrine/paracrine loop such that the mitogenic potential of EGF is selectively enhanced in tumors as compared to normal cells. Similarly, the HGF-R or the Met protein is overexpressed in tumors.
When comparing normal epithelial cells to epithelial tumor cells, the HGF-R is over-expressed, up to 100-fold in thyroid papillary carcinomas (Di Renzo et al., 1992; Prat et al., 1991) . To investigate a possible mechanism to explain this observation, Ivan et al. (1997) expressed activated Ras under the control of an inducible promoter in the R18 human thyroid cell line and found that HGF-R expression increased fourfold. In a paracrine fashion, the role of increased HGF-R expression would be to increase tumor sensitivity to HGF secreted from adjacent stromal cells. However, the authors found that this increased sensitivity to HGF was not translated into a mitogenic response, as one would predict. In fact, the role of increased HGF-R expression may be to provide a motogenic signal to tumor cells, allowing for invasive cell growth (reviewed in Jiang & Hiscox, 1997).
Receptor dimerization
In order for a proto-oncoprotein to function as an oncogene, a mutation must occur which changes the regulated activity of the gene product. For RTKs, localization to the plasma membrane may serve two functions with respect to regulation of receptor activity. One function would be to allow the receptor to bind its respective growth factor, since the ligands do not diuse across the plasma membrane. A second function for localizing a RTK to the plasma membrane may be to prevent or minimize unregulated activation of cytoplasmic proteins due to the intrinsic, basal tyrosine kinase activity of RTKs. Through mutations or the process of gene rearrangement, oncogenic RTKs bypass both of these functions.
The nerve growth factor receptor (NGF-R) undergoes a gene rearrangement with tropomyosin (MartinZanca et al., 1986) , hence the name trk (tropomyosin receptor kinase). The extracellular domain of the NGF-R is lost and tropomyosin is fused to the kinase domain. Similarly, the HGF-R undergoes gene rearrangement when sequences from chromosome 1 called tpr (translocated promoter region) fuse upstream with the HGF-R kinase domain (Cooper et al., 1984; Park et al., 1986) . The resulting Tpr-Met hybrid protein lacks the extracellular and transmembrane domain of the HGF-R. It was determined from sitedirected mutagenesis studies that the leucine zipper motif of Tpr was necessary for dimerization of TprMet (Rodrigues and Park, 1993) . The inability to form dimers also correlated with the loss of autophosphorylation of Tpr-Met and focus forming activity.
Over-expression of p185erbB2 occurs in approximately 33% of primary breast and ovarian tumors. A point mutation (V664?E) in the putative transmembrane domain renders p185erbB2 constitutively active, leading to Shc phosphorylation and activation of MAPK (Nowak et al., 1997) . Analysis of the physical properties of this mutant receptor determined that it is capable of forming dimers. Also, a chimeric p185erbB2 receptor containing the transmembrane domain of glycophorin A was capable of dimerization, suggesting that amino acid sequences outside the transmembrane domain are necessary for receptor dimerization (Burke et al., 1997) . Although the p185erbB2/glycophorin A chimera could form a dimer, it was unable to induce a transformed phenotype in cells. Thus, dimerization may be necessary, but is not sucient for transforming activity. These results suggest that constitutive or unregulated kinase activity may be the driving force that determines the oncogenic potential of RTKs and that dimerization may be an important feature of regulated RTK activity.
Oncostatin M
There is some indication that there is cross-talk between the RTKs and the cytokine oncostatin M receptor (OSM-R) which may play a role in oncogenesis. Oncostatin M is a 28 kDa glycoprotein cytokine produced by activated T cells, macrophages and phorbol ester-treated U937 leukemia cells (Zarling et al., 1986 ). OSM appears to act through a two subunit cell surface receptor, typical of cytokine receptors. The gp 130-signal transducing protein is a shared component of the Type I and Type II OSM-R. The Type I receptor consists of gp 130 and the leukemia inhibitory factor receptor b (LIF-Rb) and also binds leukemia inhibitory factor (LIF). The Type II receptor consists of gp 130 and the 180 kDa oncostatin M receptor b (OSM-Rb; gp 180) and does not bind LIF. It is the Type II receptor which appears to transduce most of the speci®c signals activated only by OSM and not by LIF (Thoma et al., 1994) . The two subunits of the receptor form a dimer upon ligand binding and are coupled to tyrosine phosphorylation, although the receptor does not possess any endogenous kinase activity (Ihle and Kerr, 1995) . One of the many eects of OSM is its ability to suppress growth of some types of tumor cells (Liu et al., 1997a) . However, OSM is also able to stimulate growth of some types of cancer, such as Kaposi's sarcoma (Miles et al., 1992; Nair et al., 1992) , while having no eect on other types, such as colon cancer (Horn et al., 1990) .
The signal transduction pathways activated by OSM result in tyrosine phosphorylation of multiple proteins (Auguste et al., 1997; Schieven et al., 1992) , downregulation of EGF-R-mediated cellular proliferation (Spence et al., 1997) and a decrease in c-myc expression (Liu et al., 1997a) . The OSM-R itself is also tyrosine phosphorylated on both the gp 130 and gp 180 subunits (Auguste et al., 1997) . However, this is not autophosphorylation as cytokine receptors do not contain a catalytic domain (Ihle and Kerr, 1995; Taniguchi, 1995) .
Activation of the OSM-R leads to recruitment of the JAK/STAT (Janus kinase/signal transduction activation of transcription) pathway. JAK is a tyrosine kinase and has been shown to activate Ras, leading to Raf, MEK and ultimately MAPK activation in response to OSM stimulation of HeLa (Stancato et al., 1997) . In addition, OSM is also capable of activating PI3-K (Ihle and Kerr, 1995) . MAPK activation is responsible for serine phosphorylation of the STAT proteins which then act as transcription factors. However, it appears that STAT proteins require both serine and tyrosine phosphorylation for activity (Wen et al., 1995) . It is activation of the JAK/ STAT pathway which appears to be responsible for the growth inhibitory eects of OSM through changes in gene transcription (Stancato et al., 1997) . It is not entirely clear what pathway is responsible for the growth-stimulatory eects of OSM but there is some evidence that the JNK (c-jun N-terminal kinase) pathway is involved (Liu et al., 1997b) . This divergent signaling by OSM may be the result of cell-type speci®c expression of signal transduction proteins as well as OSM receptor subunits.
Recently, cross-talk between RTKs and cytokine receptors have been observed with the EGF-R and the growth hormone receptor, respectively. It has been shown that growth hormone-stimulated activation of JAK is able to tyrosine phosphorylate the EGF-R leading to activation of the MAPK signaling pathway, independent of EGF-R kinase activity and EGF binding (Yamauchi et al., 1997) . Phosphorylation of the EGF-R results in an interaction between the receptor and Grb2 which initiates the MAPK signaling cascade, demonstrating an interaction between cytokine receptors and RTKs. In those experiments, the cytokines IL-6 and LIF were unable to stimulate EGF-R phosphorylation, while OSM was not tested (Yamauchi et al., 1997) . However, coadministration of OSM is able to inhibit the proliferation induced by EGF and basic ®broblast growth factor (bFGF) in some breast cancer cell lines (Liu et al., 1997a) . This may be due to a dominant growth-inhibitory signal from the OSM-R, preventing RTK-dependent signaling for cellular proliferation.
It is interesting to speculate on the functional signi®cance of this cross-talk between cytokine receptors and RTKs. Both growth-stimulatory and growth-inhibitory responses are seen with OSM. In some cases, this cross-talk may serve as an inhibitory pathway to impede uncontrolled cellular proliferation. However, it appears that during the oncogenic process, constitutively activated RTKs may over-ride the growth-inhibitory mechanisms of oncostatins or conversely, RTKs may utilize OSM-dependent pathways, such as the JAK/STAT pathway, as a synergistic mechanism to promote unregulated cellular proliferation.
Phosphoinositide 3-kinase
Phosphoinositide 3-kinase (PI3-K) can now be added to the list of proto-oncogenes. PI3-K is a heterodimer consisting of an 85 kDa regulatory subunit and a 110 kDa catalytic subunit that phosphorylates lipids (reviewed in Kapeller and Cantley, 1994) . Recently, the catalytic subunit of PI3-K was cloned from the genome of the avian sarcoma virus 16 (Chang et al., 1997) . The viral gene, termed v-p3k, has a 14 amino acid deletion at the amino terminus and is fused with the retroviral gag gene product. In addition, v-p3k diers from c-p3k in that there are four missense mutations, outside the kinase domain. However, these mutations do not inhibit the catalytic activity of v-p3k. In fact, the focus forming activity of v-p3k is ten times more ecient than c-p3k. These data demonstrate that PI3-K is an essential component of the cellular machinery for cellular proliferation.
Many of the RTKs and cytokine receptors that control cell growth also regulate PI3-K activity. Mitogenic signaling from the bPDGF-R requires PI3-K activity in ®broblasts as determined by site-directed mutagenesis of tyrosines that are known to associate with PI3-K (Valius and Kazlauskas, 1993) . In MCF-7 human breast cancer cells, IGF-1-dependent mitogenesis requires PI3-K and is independent of MAPK (Dufourny et al., 1997) . PI3-K activity is also required for interleukin-2 (IL-2)-dependent control of lymphoid cell growth (Monfar et al., 1995) .
The colony-stimulating factor receptor (CSF-1R) is encoded by the c-fms proto-oncogene and binds macrophage-CSF. The CSF-1R is structurally related to the a and b platelet-derived growth factor receptors (PDGF-R), and the c-ret proto-oncogene product, in that these receptors have a kinase domain that is disconnected by a kinase insert domain. CSF-1 regulates macrophage proliferation, dierentiation, and survival through the CSF-1R. Of the many signal transduction pathways that are activated by the CSF-1R (reviewed in Hamilton, 1997) , the PI3-K pathway may be important in malignant cell growth. Evidence for this comes from immunohistochemical studies of breast tumor specimens which demonstrated that 72% of CSF-1R positive carcinomas had receptors that were phosphorylated at Tyr723, which is the PI3-K recognition site of this receptor (Flick et al., 1997) .
Akt
Akt is a proto-oncogene activated by phospholipids produced PI3-K. The two SH2 domains of the 85 kDa subunit associate with speci®c phosphotyrosines on RTKs which eectively brings the 110 kDa subunit in close proximity to the plasma membrane. There, it catalyzes the phosphorylation of membrane-bound phosphoinositides at the D-3 hydroxyl of myoinositol, producing the second messengers phosphatidylinositol 3-phosphate [PIP], phosphatidylinositol 3,4-bisphosphate [PI(3,4)P 2 ], and phosphatidylinositol 3,4,5-trisphosphate [PI(3,4,5)P 3 ]. The target of the latter two phospholipids is the proto-oncogene Akt (Franke et al., 1997; Stokoe et al., 1997)] . Akt is also known at Protein Kinase B (PKB) and RACPK (Related to A and C Protein Kinase).
v-Akt was cloned from the genome of the AKT8 virus (Bellacosa et al., 1991) . Although the nucleotide sequence for v-akt has ®ve G?A transitions, the amino acid sequence is identical to that of c-Akt. The v-akt oncogene is the product of a recombination between nucleotides from the viral gag gene, 785 basepair (bp) downstream from the gag ATG codon, and 60 bp upstream of the c-akt ATG codon. An additional 3 bp were inserted between the gag and cAkt sequences producing a 63 nucleotide insert which, when translated, retains the c-Akt coding sequence. Thus, the v-Akt gene product is a hybrid protein consisting of Gag/63 bp/c-Akt. This gene product was immunoprecipitated from AKT8-transformed mink cells, suggesting that v-akt is a cellular proliferation signal (Bellacosa et al., 1991) . As further evidence to implicate v-akt in malignant cell growth, Akt2, a homologue of Akt, is over-expressed in some human ovarian carcinoma cell lines and primary tumors (Cheng et al., 1992) .
c-Akt consists of 480 amino acids where amino acids 1 ± 147 compose the AH (Akt homology) domain and amino acids 1 ± 106 are referred to as the PH (pleckstrin homology) domain. The AH and PH domains are involved in protein-protein interactions as well as the interaction with phospholipids. The membrane-bound phospholipids, PI(3,4)P 2 and PI(3,4,5)P 3 , bind to the pleckstrin homology (PH) domain of Akt (Figure 1 ), thus recruiting Akt to the plasma membrane and activating its kinase activity (Franke et al., 1997; Klippel et al., 1997; Stokoe et al., 1997) . When Akt binds these inositol phosphates, it becomes phosphorylated, by an unknown kinase, and Akt protein kinase activity increases (Stokoe et al., 1997) . Thus, Akt is the target of phospholipid second messengers.
PDGF, EGF and bFGF are potent activators of PI3-K and activation of their respective receptors increases Akt kinase activity (Burgering and Coer, 1995; Franke et al., 1995) . Thus, PI3-K functions to link growth factor receptors with Akt. So then, what does Akt phosphorylate? Recently, the apoptotic/antiapoptotic protein, BAD, has been identi®ed as an Akt substrate where phosphorylation of BAD is regulated by the growth factors PDGF and IGF-1 (Datta et al., 1997) , as well as the cytokines, IL-2 (Ahmed et al., 1997) and IL-3 (del Peso et al., 1997) . The signi®cance of these ®ndings is that when phosphorylated, BAD functions as an anti-apoptotic protein, promoting cell survival (Zha et al., 1996) . Thus, growth factors and cytokines mediate proliferative as well as anti-apoptotic signals. At this time, it has not been determined whether v-Akt phosphorylates BAD. However, it is tempting to speculate that BAD will be a substrate for v-Akt. As a universal mechanism, maintenance of cell survival by phosphorylation of BAD would serve to insure the transforming potential of oncogenes.
Glycogen synthase kinase 3 (GSK3) is another substrate for Akt phosphorylation. Serine phosphorylation of GSK3 results in inactivation of GSK3 (Sutherland et al., 1993) which may disrupt the degradation pathway for free b-catenin in the cell. This result is signi®cant because excess b-catenin has been shown to play a role in tumorigenesis due to its transcriptional activity (Rubinfeld et al., 1997) .
b-catenins
RTKs may also transduce oncogenic signals through bcatenins (Figure 1 ). Evidence suggests that there are two dierent roles played by b-catenins in the cell. One role casts b-catenins as structural components of the cell adhesion/actin cytoskeleton network (Daniel and Reynolds, 1997) . Another role casts free b-catenins as signaling molecules involved in gene transcription . Both of these functions may contribute to b-catenin involvement in the development of cancer. The loss of cell/cell adhesion, mediated by bcatenins, may be a factor in anchorage-independent cell growth and cancer metastasis. In addition, gene transcription mediated by b-catenins may turn on genes required for cellular proliferation or genes with an anti-apoptotic function (Peifer, 1997) . RTKs may be directly or indirectly involved in both functions of bcatenins.
Cadherins are transmembrane glycoproteins which provide an anchor through cell-cell contact. Intracellularly, cadherins interact directly with b-catenins which provide a link to the actin cytoskeleton through an interaction with a-catenin. Loss of this link is thought to be involved in the development of metastatic cancers (reviewed in Daniel and Reynolds, 1997) . Activation of RTKs, particularly by EGF and HGF/SF, has been shown to induce scattering of human cancer cells via tyrosine phosphorylation of b-catenin (Shibamoto et al., 1994) . Whether the phosphorylation is mediated by the RTK, or through activation of a soluble protein tyrosine kinase by the RTK, is not yet clear. However, a direct interaction has been shown between the EGF-R and b-catenin in vitro and EGF induces immediate b-catenin phosphorylation (Hoschuetzky et al., 1994) . It is possible that phosphorylation of b-catenin severs its interaction with the actin cytoskeleton (Daniel and Reynolds, 1997) . It is also possible that phosphorylation of b-catenin increases the pool of free b-catenin in the cell. This may be the link between activation of RTKs and cellular growth, that is characterized by the loss of contact inhibition, which is common in metastatic tumor formation.
In addition to its role in cell-cell interactions, free bcatenin plays a role in cellular signal transduction that has only recently been identi®ed (Peifer, 1997) . Free bcatenin is capable of forming a complex with DNA binding proteins of the T cell factor (Tcf) and lymphoid enhancer factor (Lef) families. Tcf and Lef interact with b-catenin and the subsequent regulation of gene transcription is thought to play an important role in tumorigenesis by activating genes involved in proliferation and/or genes with anti-apoptotic functions.
The levels of free b-catenin, as well as its stability, can be increased in some forms of cancer, leading to unregulated gene transcription. Some colon cancer cell lines are marked by the lack of tumor suppressor, adenomatous polyposis coli (APC), which leads to the constitutive activation of b-catenin-mediated signal transduction . In addition, deletions, truncations, and point mutations have been found in both APC and b-catenin in colon cancer cell lines . The mutations in APC disrupt interactions with b-catenin and lead to constitutive transcriptional activity of b-catenin. Deletions or point mutations in b-catenin either remove serines or change serines to other amino acids. Interestingly, these serines are potential phosphorylation sites for GSK3 . As a functional consequence, loss of serines in b-catenin leads to increased transcriptional activity and insensitivity to APC-mediated down-regulation of b-catenin.
In melanoma cell lines, very high levels of free bcatenin are often present. As in colon cancer cell lines, point mutations resulting in the loss of critical serines or truncations of the amino terminal region of bcatenin have been detected. In addition, mutations and loss of APC were found in melanoma cell lines. A single point mutation, S37?F, appears to be responsible for the stabilization of b-catenin and a greater than tenfold increase in the half life of the protein in the cell (Rubinfeld et al., 1997) . The loss of serines reduced phosphorylation of b-catenin, producing higher levels of free b-catenin which is capable of regulating transcriptional activity.
RTKs regulate the activity of b-catenin by two mechanisms. First RTKs may be responsible for direct phosphorylation of b-catenin which results in a loss of contact with the actin cytoskeleton and ultimately a loss of cell/cell adhesion (Daniel and Reynolds, 1997) . This may contribute to cancer metastasis. Secondly, RTKs may regulate the transcriptional activity of bcatenin via a PI3-K dependent pathway.
RTKs activate PI3-K to produce phospholipid second messengers which are involved in activation of Akt (Franke et al., 1997) . Akt then phosphorylates and inhibits the activity of GSK3. GSK3b has been shown to phosphorylate APC (Rubinfeld et al., 1996) and bcatenin (Peifer et al., 1994) . Inhibition of GSK3 activity prevents phosphorylation of APC. Formation of a complex between b-catenin, APC, and GSK3 is dependent upon phosphorylation of APC (Rubinfeld et al., 1996) . It is the formation of this complex which is responsible for degradation of excess free b-catenin. Thus, activation of RTKs disrupts degradation of bcatenin. This pool of free b-catenin is then able to function as a transcriptional activator and turn on genes involved in proliferation and/or inhibition of apoptosis.
Because the GSK3/APC/b-catenin complex is not formed due to inactivation of GSK3 in RTK stimulated cells, APC may then be capable of playing a role in cell migration and motility. Nathke et al., (1996) have shown that APC localizes to the ends of microtubules in actively migrating areas of epithelial cell membranes. This localization and stimulation with HGF indicate that APC plays an active role in cell migration. In addition, APC is involved in normal cell migration from the crypt in the intestine. Together these data indicate that APC is a key component of cell migration. Then it is possible that, in RTK stimulated cells in which GSK3 is inactivated by Akt phosphorylation, APC may be involved in aberrant migratory activity associated with tumor progression.
Autocrine/paracrine loops
In addition to receptor tyrosine kinases, growth factors may also function as oncogenes. Retroviruses contain within their genome oncogenic forms of growth factors. For example, although the PDGF receptors are not proto-oncogenes, v-sis, which is a homologue of the PDGF B chain, is an oncogene. Inappropriate expression of v-sis eectively activates the PDGF-R to produce a persistent mitogenic signal in cells.
The inappropriate expression of a growth factor can function as an oncogenic mechanism to induce cell growth or cell survival. Aside from promoting cell proliferation and dierentiation, oncogenic Ras can also induce over-expression of the growth factor IGF-1 (Dawson et al., 1995) . One of the major functions of IGF-1 is to function as a survival factor in serum, protecting cells from apoptosis. The IGF-1R activates PI3-K whose phospholipid products bind to the PH domain of Akt, producing an anti-apoptotic signal. In the cascade of signals, Akt binds PI3-K-generated phospholipids which activate Akt to phosphorylate BAD, which is an anti-apoptotic signal in an IL-3-dependent hematopoietic cell line (Zha et al., 1996) . Therefore, activated Ras may function to eect autocrine loops that produce growth factors, such as IGF-1, whose function is to maintain cell survival by inhibiting apoptosis, thus allowing mutated cells to proliferate (Figure 1 ).
Concluding remarks
In conclusion, it is not only RTKs and their growth factor ligands that function as oncogenes. Many of the proteins involved in RTK signal transduction are also capable of acting as oncogenes, independent of RTK stimulation. RTKs have their eect on cellular physiology via a number of dierent mechanisms, including increased proliferation, disruption of apoptosis, disruption of normal cytoskeletal interactions, increased cell motility, and invasive cell growth. RTK and Ras-mediated production of growth factors can activate a number of these pathways due to autocrine and paracrine loops. In addition, activation of PI3-K by oncogenic RTKs can lead to changes in gene transcription, cell motility, cytoskeletal changes, and anti-apoptotic signals; all of which could contribute to oncogenesis. Moreover, there is evidence that there may be cross-talk between the RTKs and the oncostatin cytokine receptor which could in¯uence proliferation. The picture of RTK signal transduction which leads to oncogenesis is far from complete. However, as we learn more about oncogenes and signal transduction pathways, we are beginning to appreciate that oncogenes utilize multiple pathways for their selective growth advantages. De®ning these pathways and mechanisms will ultimately lead to a better understanding of the oncogenic process, which may provide more selective methods for the treatment of cancers.
